Johnson & Johnson Expects Tariffs to Cost Company $400 Million

Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports. That move is widely seen as a first step toward imposing new levies. Earnings and revenue both beat estimates for the quarter. Johnson & Johnson CFO Joe Wolk joined Bloomberg Open Interest to talk about how tariffs could hit the industry and the drug maker’s bottom line. ——– More on Bloomberg Television and Markets